OWCP - OWC Pharmaceutical Research Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0102
-0.0008 (-7.36%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0110
Open0.0110
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0096 - 0.0115
52 Week Range0.0030 - 0.1539
Volume9,836,008
Avg. Volume8,562,824
Market Cap2.673M
Beta (5Y Monthly)0.80
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • OWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA
    PR Newswire

    OWC Israel's Patent for Cannabis Based Extracts and Topical Formulations for Use in Skin Disorders, Is Allowed for Issuance as a Patent in the USA

    OWC Pharmaceutical Research Corp. (OTCQB: OWCP) ("OWC"), represented by its wholly-owned subsidiary, One World Cannabis Ltd., a company organized and existing under the laws of Israel ("OWC-Israel"), announced that, on December 9, 2019, the United States Patent and Trademark Office issued a Notice of Allowance indicating that OWC Israel's Patent Application No. 15/629,230 directed to cannabis based extracts and topical formulations for use in skin disorders, is allowed for issuance as a patent. The allowed patent application, which indicates a unique modality of treatment, covers a method of treating or inhibiting an inflammatory skin disease in a human in need thereof comprising topically administering to the human a therapeutically effective amount of a pharmaceutical composition comprising carrier formulations described in the claims and cannabis oil comprising cannabidiol and tetrahydrocannabinol, wherein the inflammatory skin disease is selected from a large group of skin conditions, including but not limited to psoriasis.

  • PR Newswire

    OWC Pharmaceutical Research Corp and STENOCARE to Enter Partnership to Develop Advanced Medical Cannabis Products

    The new relationship will provide market access to OWC's technologies and will accelerate STENOCAREs long term strategy to supplement its high quality generic medical cannabis products with differentiated products that are formulated to target specific patient groups suffering from specific conditions. The companies wish to cooperate in order to jointly develop and promote the sale and distribution of products within STENOCARE's current core markets (Denmark, Ireland) and potentially in new territories to be targeted by STENOCARE. OWC will provide its expertise in medical research and clinical trials for cannabis-based novel therapeutic products and treatments, backed by its extensive Intellectual Property Portfolio.

  • PR Newswire

    OWC Pharmaceutical Research Corp. to Report Top Line Results (TLR) for a Safety Study on Its Cannabis-based Tablets

    RAMAT GAN , Israel , Oct. 7, 2019 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, ...

  • PR Newswire

    OWC Pharmaceutical Research Received a Permit for a Cannabis Based Ointment Efficacy Trial

    RAMET GAN, Israel , Aug. 5, 2019 /PRNewswire/ --  OWC   Pharmaceuticals Research Corp.  ("OWC") (OTCQB: OWCP) announced that, on July 18, 2019 , it received long-awaited approval from the Israeli ...